Detection and Analysis of MBC With Heterogeneous ER Expression

Chemotherapy Versus Endocrine Therapy in Metastatic Breast Cancer Patients With Heterogeneous Estrogen Receptor Expression

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05392985

Enrollment

Registered

2022-05-26

Start date

2022-01-15

Completion date

2022-12-15

Last updated

2024-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

To investigate the treatment pattern and efficacy of MBC patients with ER heterogeneity using a novel convenient way of 18F-fluoroestradiol positron emission tomography/computed tomography (18F-FES PET/CT).

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients received 18F-FES PET/CT in Fudan University Shanghai Cancer Center from 2017-2021. * Patients had both FES positive (FES+) and negative (FES-) lesions in FES exam. * Patients received further treatment.

Exclusion criteria

* Incomplete medical records.

Design outcomes

Primary

Measure	Time frame	Description
PFS	6 weeks	Progression free survival

Secondary

Measure	Time frame	Description
Adverse events	6 weeks	Number of participants with treatment-related adverse events as assessed by CTCAE v 5.0

Countries

China

Outcome results